ORTIN GLOBAL LIMITED vs TORRENT PHARMACEUTICALS L

A side-by-side comparison of ORTIN GLOBAL LIMITED (ORTINGLOBE) and TORRENT PHARMACEUTICALS L (TORNTPHARM) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

ORTINGLOBE logo
ORTIN GLOBAL LIMITED
ORTINGLOBE
₹15.33+0.20%
VS
TORNTPHARM logo
TORRENT PHARMACEUTICALS L
TORNTPHARM
₹4,954-2.21%
Leads on the numbers
The verdict

On the numbers, TORRENT PHARMACEUTICALS L leads ORTINGLOBE vs TORNTPHARM on 10 of 14 metrics (1 undecided). See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

  • Valuation22
  • Profitability04
  • Growth01
  • Size & financial health13

Valuation

Even

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

-13.50
P/E ratio
77.50
10.89
P/B ratio
18.67
0.00%
Dividend yield
0.76%
₹-0.91
EPS
₹63.92

Profitability

TORNTPHARM takes 4/4

How efficiently each company turns capital and sales into profit. Higher is better.

-59.68%
Return on equity
27.40%
-32.14%
Return on capital
15.00%
-175.61%
EBITDA margin
33.00%
-740.00%
Net margin
15.29%

Growth

TORNTPHARM takes 1/2

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

-74.46%
Revenue CAGR (3Y)
13.27%
—
Profit CAGR (3Y) even
19.75%

Size & financial health

TORNTPHARM takes 3/4

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹13 Cr
Market cap
₹1.68L Cr
₹0 Cr
Revenue
₹13,980 Cr
₹-1 Cr
Net profit
₹2,138 Cr
0.81
Debt / equity
1.69
ORTIN GLOBAL LIMITED
  • + ["Debtor days have improved from 260 to 178 days."]
  • − ["Stock is trading at 9.79 times its book value", "Company has low interest coverage ratio.", "The company has delivered a poor sales growth of -45.0% over past five years.", "Promoter holding is low: 1.23%", "Company has a low return on equity of -72.7% over last 3 years.", "Contingent liabilities of Rs.24.3 Cr.", "Company might be capitalizing the interest cost", "Company has high debtors of 178 days.", "Promoter holding has decreased over last 3 years: -6.13%"]
TORRENT PHARMACEUTICALS L
  • + ["Company is expected to give good quarter", "Company has a good return on equity (ROE) track record: 3 Years ROE 26.2%", "Company has been maintaining a healthy dividend payout of 57.8%"]
  • − ["Stock is trading at 20.4 times its book value", "Promoter holding has decreased over last quarter: -7.53%", "The company has delivered a poor sales growth of 11.8% over past five years.", "Company might be capitalizing the interest cost"]
ORTIN GLOBAL LIMITED full analysis TORRENT PHARMACEUTICALS L full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.